DK2391620T3 - Alkylaminosubstituerede dicyanopyridiner og deres aminosyreester-prodrugs - Google Patents

Alkylaminosubstituerede dicyanopyridiner og deres aminosyreester-prodrugs

Info

Publication number: DK2391620T3
Authority: DK; Denmark
Prior art keywords: prodrugs; amino acid; alkylamino substituted; acid este; substituted dicyanopyridines
Prior art date: 2009-01-29

Application number

DK10700508.4T

Other languages

English (en)

Inventor

Katja Zimmermann

Peter Nell

Frank Süssmeier

Barbara Albrecht-Küpper

Alexandros Vakalopoulos

Daniel Meibom

Joerg Keldenich

Hans-Georg Lerchen

Ursula Krenz

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-29

Filing date

2010-01-19

Publication date

2014-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41724154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2391620(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-01-19 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2014-08-11 Application granted granted Critical

2014-08-11 Publication of DK2391620T3 publication Critical patent/DK2391620T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Crystallography & Structural Chemistry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

DK10700508.4T 2009-01-29 2010-01-19 Alkylaminosubstituerede dicyanopyridiner og deres aminosyreester-prodrugs DK2391620T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102009006602A DE102009006602A1 (de)	2009-01-29	2009-01-29	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
PCT/EP2010/000262 WO2010086101A1 (de)	2009-01-29	2010-01-19	Alkylamino-substituierte dicyanopyridine und deren aminosäureester-prodrugs

Publications (1)

Publication Number	Publication Date
DK2391620T3 true DK2391620T3 (da)	2014-08-11

Family

ID=41724154

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK14155583.9T DK2743270T3 (da)	2009-01-29	2010-01-19	Alkylamino-substituerede dicyanopyridiner og deres aminosyreester-prodrugs
DK10700508.4T DK2391620T3 (da)	2009-01-29	2010-01-19	Alkylaminosubstituerede dicyanopyridiner og deres aminosyreester-prodrugs

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK14155583.9T DK2743270T3 (da)	2009-01-29	2010-01-19	Alkylamino-substituerede dicyanopyridiner og deres aminosyreester-prodrugs

Country Status (42)

Country	Link
US (3)	US8420825B2 (da)
EP (2)	EP2743270B1 (da)
JP (2)	JP5693469B2 (da)
KR (2)	KR101717305B1 (da)
CN (2)	CN104844687B (da)
AR (1)	AR075050A1 (da)
AU (1)	AU2010207786B2 (da)
BR (1)	BRPI1007308A2 (da)
CA (2)	CA2962039A1 (da)
CO (1)	CO6400193A2 (da)
CR (1)	CR20110407A (da)
CU (1)	CU24037B1 (da)
CY (2)	CY1115403T1 (da)
DE (1)	DE102009006602A1 (da)
DK (2)	DK2743270T3 (da)
DO (1)	DOP2011000243A (da)
EA (1)	EA019275B1 (da)
EC (1)	ECSP11011235A (da)
ES (2)	ES2614702T3 (da)
GT (1)	GT201100205A (da)
HK (1)	HK1211308A1 (da)
HN (1)	HN2011002037A (da)
HR (2)	HRP20140714T1 (da)
HU (1)	HUE032008T2 (da)
IL (1)	IL214019A0 (da)
JO (1)	JO2927B1 (da)
LT (1)	LT2743270T (da)
MA (1)	MA33000B1 (da)
MX (1)	MX2011007800A (da)
MY (1)	MY156434A (da)
NZ (1)	NZ594267A (da)
PE (2)	PE20120430A1 (da)
PL (2)	PL2391620T3 (da)
PT (2)	PT2743270T (da)
RS (1)	RS53448B (da)
SG (1)	SG172968A1 (da)
SI (2)	SI2391620T1 (da)
TN (1)	TN2011000370A1 (da)
TW (2)	TWI457126B (da)
UA (1)	UA104613C2 (da)
UY (1)	UY32393A (da)
WO (1)	WO2010086101A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004042607A1 (de)	2004-09-03	2006-03-09	Bayer Healthcare Ag	Substituierte Phenylaminothiazole und ihre Verwendung
DE102006042143A1 (de)	2006-09-08	2008-03-27	Bayer Healthcare Aktiengesellschaft	Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de)	2007-07-27	2009-01-29	Bayer Healthcare Ag	Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) *	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
DE102008013587A1 (de)	2008-03-11	2009-09-17	Bayer Schering Pharma Aktiengesellschaft	Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
CA2726020C (en)	2008-05-29	2016-08-16	Bayer Schering Pharma Aktiengesellschaft	2-alkoxy-substituted dicyanopyridines and use thereof
DE102008062567A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) *	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de)	2010-06-30	2012-01-05	Bayer Schering Pharma Aktiengesellschaft	Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) *	2010-09-02	2012-03-08	Bayer Pharma Aktiengesellschaft	Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
MX2015008114A (es)	2012-12-21	2015-11-06	Sanofi Sa	Derivados de exendina-4.
CN105792826A (zh) *	2013-12-12	2016-07-20	拜耳制药股份公司	作为针对肾病的药物的腺苷a1激动剂
US9318574B2 (en)	2014-06-18	2016-04-19	International Business Machines Corporation	Method and structure for enabling high aspect ratio sacrificial gates
BR112017023852A2 (pt) *	2015-05-06	2018-07-17	Bayer Pharma Aktiengesellschaft	Processo para preparar monocloridrato de l- alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il] metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4- il]fenoxi}etil-l-alanila.
WO2017137528A1 (en)	2016-02-12	2017-08-17	Charité - Universitätsmedizin Berlin	Adenosine a1 receptor agonist for use in treatment of status epilepticus
WO2018108884A1 (de)	2016-12-16	2018-06-21	Bayer Pharma Aktiengesellschaft	Pharmazeutische tablettenformulierung
WO2018153898A1 (de) *	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
WO2018153899A1 (de)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
WO2018153897A1 (de)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern
WO2018153900A1 (de) *	2017-02-22	2018-08-30	Bayer Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern
WO2018153895A1 (de)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
WO2018219804A1 (en) *	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Self-microemulsifying drug delivery systems
WO2018219801A1 (en)	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Immediate-release extrudates
WO2019180072A1 (en)	2018-03-22	2019-09-26	Bayer Pharma Aktiengesellschaft	Parenteral pharmaceutical composition comprising neladenoson bialanate
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4052510A (en)	1974-12-18	1977-10-04	Sandoz, Inc.	4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (da)	1992-12-29	1997-03-01	Takeda Pharm Industry Co Ltd
EP0765327B1 (en)	1994-06-16	1999-07-21	Pfizer Inc.	Pyrazolo and pyrrolopyridines
DE4430638A1 (de)	1994-08-29	1996-03-07	Bayer Ag	Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja)	1995-11-09	1997-05-20	Ono Pharmaceut Co Ltd	一酸化窒素合成酵素阻害剤
CA2241567A1 (en)	1996-01-17	1997-07-24	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
EP0885192B8 (en)	1996-01-29	2012-05-16	The United States of America, Represented by the Secretary, Department of Health and Human Services	Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
JPH10324687A (ja)	1997-02-19	1998-12-08	Nippon Soda Co Ltd	ピロール化合物、製法および農園芸用殺菌剤
EP0984935A1 (de)	1997-05-30	2000-03-15	Basf Aktiengesellschaft	Verfahren zur herstellung substituierter thiopyridine
IL133604A0 (en)	1997-07-16	2001-04-30	Novo Nordisk As	Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
US6632823B1 (en)	1997-12-22	2003-10-14	Merck & Co., Inc.	Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de)	1999-10-01	2001-10-04	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
YU63802A (sh)	2000-02-25	2005-06-10	F. Hoffmann-La Roche Ag.	Modulatori adenozinskih receptora
WO2002006237A1 (en) *	2000-07-18	2002-01-24	Yamanouchi Pharmaceutical Co., Ltd.	Medicine comprising dicyanopyridine derivative
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
JP2004515543A (ja)	2000-12-11	2004-05-27	イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー	有害無脊椎動物を防除するためのキナゾリノン類およびピリジニルピリミジノン類
HUP0303538A2 (hu)	2000-12-21	2005-02-28	Bristol-Myers Squibb Co.	Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
DE10110438A1 (de)	2001-03-05	2002-09-19	Bayer Ag	Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110747A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de)	2001-03-07	2002-09-19	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de)	2001-03-30	2002-10-02	Bayer Ag	Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de)	2001-03-30	2002-10-10	Bayer Ag	Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de)	2001-07-16	2003-01-30	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) *	2001-12-11	2003-06-18	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja)	2001-12-20	2003-07-03	Yamanouchi Pharmaceut Co Ltd	２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
EP1506189A1 (en)	2002-04-26	2005-02-16	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
DE60321920D1 (de) *	2002-08-02	2008-08-14	Dow Global Technologies Inc	Metallkomplexe der gruppe 4 des pse, die 4-aryl substituierte, tricyclische indenylderivate enthalten
EP1388342A1 (en)	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
JP2006501217A (ja)	2002-08-12	2006-01-12	スージェン・インコーポレーテッド	新規キナーゼ阻害剤としての３−ピロリル−ピリドピラゾールおよび３−ピロリル−インダゾール
JP2006512338A (ja)	2002-12-12	2006-04-13	ファルマシア・コーポレーション	マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２阻害剤としてのアミノシアノピリジンの使用法
AR042667A1 (es)	2002-12-26	2005-06-29	Taisho Pharmaceutical Co Ltd	Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
TW200418829A (en)	2003-02-14	2004-10-01	Avanir Pharmaceutics	Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN1856307A (zh)	2003-09-23	2006-11-01	默克公司	喹啉钾通道抑制剂
WO2005046603A2 (en)	2003-11-10	2005-05-26	Synta Pharmaceuticals, Corp.	Pyridine compounds
US20050182105A1 (en)	2004-02-04	2005-08-18	Nirschl Alexandra A.	Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
JP2007161585A (ja)	2004-06-25	2007-06-28	Taisho Pharmaceut Co Ltd	環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
CN1972941A (zh)	2004-06-25	2007-05-30	大正制药株式会社	作为crf拮抗剂的四氢吡啶取代的吡咯并嘧啶和吡咯并吡啶衍生物
DE102004032651A1 (de)	2004-07-06	2006-02-16	Bayer Healthcare Ag	Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
DE102004042607A1 (de) *	2004-09-03	2006-03-09	Bayer Healthcare Ag	Substituierte Phenylaminothiazole und ihre Verwendung
CA2580860A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
CA2602514A1 (en)	2005-03-24	2006-09-28	Bayer Healthcare Ag	Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage
US7750015B2 (en)	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007073855A1 (en)	2005-12-23	2007-07-05	Bayer Healthcare Ag	Use of adenosine a1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases
DE102006009813A1 (de)	2006-03-01	2007-09-06	Bayer Healthcare Ag	Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
JP2009535307A (ja)	2006-04-28	2009-10-01	アベキサ・リミテッド	インテグラーゼ阻害剤３
WO2008008059A1 (en)	2006-07-12	2008-01-17	Locus Pharmaceuticals, Inc.	Anti-cancer agents ans uses thereof
DE102006042143A1 (de) *	2006-09-08	2008-03-27	Bayer Healthcare Aktiengesellschaft	Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de)	2007-07-27	2009-01-29	Bayer Healthcare Ag	Substituierte Aryloxazole und ihre Verwendung
DE102007036075A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Ag	Prodrugs und ihre Verwendung
DE102007036076A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) *	2007-12-20	2009-06-25	Bayer Healthcare Ag	Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008008838A1 (de)	2008-02-13	2009-08-20	Bayer Healthcare Ag	Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
DE102008013587A1 (de)	2008-03-11	2009-09-17	Bayer Schering Pharma Aktiengesellschaft	Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
CA2726020C (en)	2008-05-29	2016-08-16	Bayer Schering Pharma Aktiengesellschaft	2-alkoxy-substituted dicyanopyridines and use thereof
DE102008062567A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Dipeptoid-Prodrugs und ihre Verwendung
DE102008062566A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Aminosäureester-Prodrugs und ihre Verwendung
DE102009006602A1 (de) *	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US8470800B2 (en)	2009-05-01	2013-06-25	Inotek Pharmaceuticals Corporation	Method of reducing intraocular pressure in humans

2009
- 2009-01-29 DE DE102009006602A patent/DE102009006602A1/de not_active Withdrawn
2010
- 2010-01-19 CA CA2962039A patent/CA2962039A1/en not_active Abandoned
- 2010-01-19 DK DK14155583.9T patent/DK2743270T3/da active
- 2010-01-19 PT PT141555839T patent/PT2743270T/pt unknown
- 2010-01-19 ES ES14155583.9T patent/ES2614702T3/es active Active
- 2010-01-19 KR KR1020117017725A patent/KR101717305B1/ko not_active Expired - Fee Related
- 2010-01-19 PE PE2011001362A patent/PE20120430A1/es active IP Right Grant
- 2010-01-19 SI SI201030685T patent/SI2391620T1/sl unknown
- 2010-01-19 SI SI201031393A patent/SI2743270T1/sl unknown
- 2010-01-19 PT PT107005084T patent/PT2391620E/pt unknown
- 2010-01-19 ES ES10700508.4T patent/ES2473966T3/es active Active
- 2010-01-19 EP EP14155583.9A patent/EP2743270B1/de active Active
- 2010-01-19 RS RS20140393A patent/RS53448B/sr unknown
- 2010-01-19 EA EA201101111A patent/EA019275B1/ru not_active IP Right Cessation
- 2010-01-19 PE PE2015000329A patent/PE20150636A1/es not_active Application Discontinuation
- 2010-01-19 PL PL10700508T patent/PL2391620T3/pl unknown
- 2010-01-19 CN CN201510167727.3A patent/CN104844687B/zh not_active Expired - Fee Related
- 2010-01-19 MX MX2011007800A patent/MX2011007800A/es active IP Right Grant
- 2010-01-19 AU AU2010207786A patent/AU2010207786B2/en not_active Ceased
- 2010-01-19 CN CN201080014887.XA patent/CN102388040B/zh not_active Expired - Fee Related
- 2010-01-19 BR BRPI1007308A patent/BRPI1007308A2/pt not_active Application Discontinuation
- 2010-01-19 NZ NZ594267A patent/NZ594267A/xx not_active IP Right Cessation
- 2010-01-19 MY MYPI2011003521A patent/MY156434A/en unknown
- 2010-01-19 LT LTEP14155583.9T patent/LT2743270T/lt unknown
- 2010-01-19 HU HUE14155583A patent/HUE032008T2/en unknown
- 2010-01-19 CA CA2750769A patent/CA2750769C/en not_active Expired - Fee Related
- 2010-01-19 PL PL14155583T patent/PL2743270T3/pl unknown
- 2010-01-19 DK DK10700508.4T patent/DK2391620T3/da active
- 2010-01-19 JP JP2011546673A patent/JP5693469B2/ja not_active Expired - Fee Related
- 2010-01-19 KR KR1020177006269A patent/KR101833188B1/ko not_active Expired - Fee Related
- 2010-01-19 EP EP10700508.4A patent/EP2391620B1/de active Active
- 2010-01-19 UA UAA201110416A patent/UA104613C2/ru unknown
- 2010-01-19 HR HRP20140714AT patent/HRP20140714T1/hr unknown
- 2010-01-19 WO PCT/EP2010/000262 patent/WO2010086101A1/de not_active Ceased
- 2010-01-19 MA MA34060A patent/MA33000B1/fr unknown
- 2010-01-19 SG SG2011050770A patent/SG172968A1/en unknown
- 2010-01-26 AR ARP100100173A patent/AR075050A1/es not_active Application Discontinuation
- 2010-01-26 UY UY0001032393A patent/UY32393A/es not_active Application Discontinuation
- 2010-01-28 TW TW099102338A patent/TWI457126B/zh not_active IP Right Cessation
- 2010-01-28 TW TW103133417A patent/TWI511968B/zh not_active IP Right Cessation
- 2010-01-28 JO JO201023A patent/JO2927B1/en active
- 2010-01-29 US US12/697,000 patent/US8420825B2/en not_active Expired - Fee Related
2011
- 2011-07-11 IL IL214019A patent/IL214019A0/en not_active IP Right Cessation
- 2011-07-25 CO CO11092821A patent/CO6400193A2/es not_active Application Discontinuation
- 2011-07-25 HN HN2011002037A patent/HN2011002037A/es unknown
- 2011-07-25 GT GT201100205A patent/GT201100205A/es unknown
- 2011-07-26 EC EC2011011235A patent/ECSP11011235A/es unknown
- 2011-07-27 CR CR20110407A patent/CR20110407A/es unknown
- 2011-07-27 DO DO2011000243A patent/DOP2011000243A/es unknown
- 2011-07-27 TN TN2011000370A patent/TN2011000370A1/fr unknown
- 2011-07-28 CU CU2011000153A patent/CU24037B1/es active IP Right Grant
2013
- 2013-03-13 US US13/801,484 patent/US8772498B2/en not_active Expired - Fee Related
2014
- 2014-06-17 US US14/306,781 patent/US20140296515A1/en not_active Abandoned
- 2014-08-01 CY CY20141100585T patent/CY1115403T1/el unknown
2015
- 2015-02-03 JP JP2015019616A patent/JP5908620B2/ja active Active
- 2015-12-10 HK HK15112176.4A patent/HK1211308A1/xx unknown
2017
- 2017-02-03 CY CY20171100159T patent/CY1118601T1/el unknown
- 2017-02-08 HR HRP20170206TT patent/HRP20170206T1/hr unknown

Also Published As

Publication number	Publication date
AR075050A1 (es)	2011-03-02
CY1115403T1 (el)	2017-01-04
CN104844687B (zh)	2019-04-02
CN102388040A (zh)	2012-03-21
CA2750769C (en)	2018-08-21
HRP20140714T1 (hr)	2014-11-21
ECSP11011235A (es)	2011-10-31
EP2743270A1 (de)	2014-06-18
CU20110153A7 (es)	2012-02-15
AU2010207786A1 (en)	2011-08-25
HK1168353A1 (en)	2012-12-28
AU2010207786B2 (en)	2015-10-22
HK1211308A1 (en)	2016-05-20
PE20150636A1 (es)	2015-05-08
US8772498B2 (en)	2014-07-08
DK2743270T3 (da)	2017-02-20
PL2743270T3 (pl)	2017-04-28
CR20110407A (es)	2012-01-02
TW201504235A (zh)	2015-02-01
MY156434A (en)	2016-02-26
UA104613C2 (en)	2014-02-25
PT2391620E (pt)	2014-06-25
WO2010086101A1 (de)	2010-08-05
IL214019A0 (en)	2011-08-31
MX2011007800A (es)	2011-11-18
JP2012516290A (ja)	2012-07-19
CN104844687A (zh)	2015-08-19
CU24037B1 (es)	2014-11-27
EP2743270B1 (de)	2016-12-21
ES2614702T3 (es)	2017-06-01
CO6400193A2 (es)	2012-03-15
GT201100205A (es)	2013-08-21
PL2391620T3 (pl)	2014-09-30
US20140296515A1 (en)	2014-10-02
US20130267700A1 (en)	2013-10-10
ES2473966T3 (es)	2014-07-08
JP5693469B2 (ja)	2015-04-01
DE102009006602A1 (de)	2010-08-05
MA33000B1 (fr)	2012-01-02
NZ594267A (en)	2013-09-27
EA201101111A1 (ru)	2012-02-28
EP2391620B1 (de)	2014-05-07
BRPI1007308A2 (pt)	2016-02-10
KR20170029029A (ko)	2017-03-14
RS53448B (sr)	2014-12-31
KR101717305B1 (ko)	2017-03-16
KR101833188B1 (ko)	2018-02-27
UY32393A (es)	2010-08-31
TW201039821A (en)	2010-11-16
CA2962039A1 (en)	2010-08-05
US8420825B2 (en)	2013-04-16
EP2391620A1 (de)	2011-12-07
HUE032008T2 (en)	2017-08-28
HRP20170206T1 (hr)	2017-04-07
HN2011002037A (es)	2013-12-02
LT2743270T (lt)	2017-02-27
CY1118601T1 (el)	2017-07-12
DOP2011000243A (es)	2017-10-15
JO2927B1 (en)	2015-09-15
TWI457126B (zh)	2014-10-21
JP2015120727A (ja)	2015-07-02
SI2743270T1 (sl)	2017-03-31
CA2750769A1 (en)	2010-08-05
EA019275B1 (ru)	2014-02-28
TN2011000370A1 (en)	2013-03-27
CN102388040B (zh)	2015-05-13
PT2743270T (pt)	2017-02-15
JP5908620B2 (ja)	2016-04-26
TWI511968B (zh)	2015-12-11
SI2391620T1 (sl)	2014-08-29
KR20110108377A (ko)	2011-10-05
US20100197609A1 (en)	2010-08-05
PE20120430A1 (es)	2012-04-21
SG172968A1 (en)	2011-08-29

Publication	Publication Date	Title
DK2391620T3 (da)	2014-08-11	Alkylaminosubstituerede dicyanopyridiner og deres aminosyreester-prodrugs
DK2539707T3 (da)	2021-07-26	Kunstige mycolsyremembraner
IL249285A0 (en)	2017-01-31	Transaminase polypeptides
EP2498885A4 (en)	2013-05-22	TOY KREISEL
EP2509515A4 (en)	2015-01-28	WITHERS
HRP20171823T1 (hr)	2018-01-12	Postupak izdvajanja nukleinskih kiselina i komplet u tu svrhu
DK2490940T3 (da)	2021-10-11	Uav-system og fremgangsmåde
BRPI1009192A2 (pt)	2015-09-22	preparação de ácido adípico
EP2501439A4 (en)	2014-11-05	FAN
DK2623507T3 (da)	2017-01-02	Morpholinonukleinsyrederivat
DK2349217T3 (da)	2019-11-04	Gamma-hydroxysmørsyre-granulat
EP2444119A4 (en)	2013-04-24	Magnetic stimulator
UA21012S (uk)	2010-10-25	Іграшка
BR112013008526A2 (pt)	2016-07-12	inibidores de quinase do tipo polo
IT1398518B1 (it)	2013-03-01	Safe milano
DK3392252T3 (da)	2024-01-08	Pyrimido-pyridazinonforbindelser og deres anvendelse
BRPI1007196A2 (pt)	2016-09-27	profármacos e derivado de espiroindolinona
FI20096351A0 (fi)	2009-12-18	Implanttijärjestelmä
BR112012001551A2 (pt)	2017-07-11	profármacos de aminoácido galantamina e peptídeo e usos dos mesmos
HRP20160900T1 (hr)	2016-09-23	Postupak za podizanje tornja i toranj
BRPI0924187A2 (pt)	2016-02-10	conjunto conector
DK2279652T3 (da)	2012-11-26	Kultivator
BR112012000805A2 (pt)	2016-02-23	revestimento mecanicamente estável
DK2468256T3 (da)	2013-11-11	Kombinationer af vildagliptin og glimepirid
DK2424408T3 (da)	2014-07-07	Tidløst identifikationspas